Environmentalists have said that there are significant challenges in front of those working to preserve the endangered pollution of vultures....
Analyst Ratings Network.com revealed that Zacks has upgraded Derma Sciences. The investment research firm has given ‘buy’ rating to the company’s shares in a research note on Wednesday, it said.
“Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns”, Zacks said.
Recently, a number of other equities research analysts released their reports on Derma Sciences. In a research note issued on Monday, Canaccord gave buy rating to shares of the company. Adding to that, it issued $9.00 price target on the shares. A day after Canaccord’s report, Piper Jaffray released a report and lowered price target on Derma Sciences. They gave neutral rating on the stock and lowered price target to $6.00 from $7.00.
Unlike Piper Jaffray, Oppenheimer issued buy rating on Derma Sciences shares in a note on August 12. Adding to that, Roth Capital also gave buy rating on the shares of Derma Sciences in a research report on August 13. Four analysts gave buy rating to the company, while one rated the company’s stock with hold rating. Currently, the company has price target of $8.65.
On Wednesday, the company’s shares traded down about 0.47% and reached $4.26. Derma Sciences’ stock has a volume of about 174,109 shares.
